ClinicalTrials.gg
RecruitingNCT06204835Updated May 22, 2024

ITGA6 Targeting NIR-II Fluorescence Image Guided Surgery

A Phase 1 interventional study of RD-Cy7 fluorophore in Hepatocellular Carcinoma, sponsored by Institute of Automation, Chinese Academy of Sciences. Recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by Institute of Automation, Chinese Academy of Sciences · Phase 1, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,314 studies in Carcinoma, Hepatocellular with a site in China — 489 open to participants now, 561 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Planned enrollment
471st of 1,038
90 · median 77
Started
2024
with 139 others
Phase 1
139 of 1,314
61 open now
Primary completion
2034-12
later than 558 of 560 live
Registered
893rd of 1,314
by date

Among the 1,314 studies in Carcinoma, Hepatocellular with a site in China, this one is the 471st largest by planned enrollment of the 1,038 interventional ones that give a count, is one of 140 that started in 2024, is one of 139 in phase 1, reaches primary completion later than 558 of the 560 other live ones, and was the 893rd registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

489 of the 1,314 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

484 more — sign in →

All 489 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,314 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

In this study, the investigators will detect hepatocellular carcinoma lesions using fluoescence imaging with ITGA6 targeting probes during tumor resection surgery. The aim is to evaluate wether intraoperative fluorescence imaging targeting ITGA6 can help to improve the detction effect of hepatocellular carcinoma, and finally help the accurate surgical resection.

The main purposes of this study include:

  1. To raise the detection rate of hepatocellular carcinoma intraoperatively using the novel NIR-II fluorescence molecular imaging and the ITGA6 targeting probe.
  2. To validate the safety and effectiveness of the proposed ITGA6 targeting probes for clinical application.
03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who have been diagnosed with hepatocellular carcinoma.
  2. Planned to receive hepatectomy.
  3. Liver function A.
  4. ITGA6 was validated highly expressed preoperatively.
  5. Aged 18 to 80, and the expected lifetime is longer than 6 months.
  6. Approved to sign the .

Exclusion criteria

Exclusion Criteria:

  1. Allergic to Cy7.
  2. Enrolled in other trials in the past 3 months.
  3. Another malignant tumor was found.
  4. Undesirable function of heart, lung, kidney, or any other organs.
  5. Unable to tolerate a hepatectomy.
  6. The researchers considered inappropriate to be included.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    RDCy7 Intraoperative Fluorescence

    The patients will receive an injection of fluorophore (RDCy7) before the surgery. Then intraoperative fluorescence imaging will be performed to guide lesion resection.

    Drug: RD-Cy7 fluorophore

Interventions

  • DrugRD-Cy7 fluorophore

    Fluorophore targeting ITGA6 that is overexpressed in HCC cells

06

What researchers measure

Primary outcomes

  1. HCC lesions

    Numbers of intraoperatively detected hepatocellular carcinoma lesions.

    Time frame: During hepatocellular resection surgery.

07

Study locations

2 of 2 sites recruiting
  • Guangdong
    Guangzhou, Guangdong, China
    Recruiting
  • Sichuan
    Luzhou, Sichuan, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — No publications available

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2034, 131 months after the start.

Of 147 non-industry phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 80. This study's planned 131 months is above that.

Counting every sponsor, half of 250 studies reached it within 49 months; a quarter within 32 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2024
First posted
Jan 12, 2024
StartActual
Jan 7, 2024
Primary completionEst.
Dec 31, 2034
CompletionEst.
Dec 31, 2039
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06204835
Lead sponsor
Institute of Automation, Chinese Academy of Sciences
Responsible party
Zhenhua Hu (Professor, Institute of Automation, Chinese Academy of Sciences) — Principal investigator
First posted
Jan 12, 2024
Start date
Jan 7, 2024
Primary completion
Dec 31, 2034 (estimated)
Completion
Dec 31, 2039 (estimated)
Last update
May 22, 2024

Study contacts

Xiaojing Shi, PhD
Contact
shixiaojing2017@ia.ac.cn
13261798652
Zhenhua Hu, Ph. D
principal investigator · Institute of Automation, Chinese Academy of Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion